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Background: Cutaneous squamous cell carcinomas (cSCC) are among the most common and highly mutated
human malignancies. Understanding the impact of DNA methylation in cSCC may provide avenues for new
therapeutic strategies.
Methods:We used reduced-representation bisulfite sequencing for DNAmethylation analysis of murine cSCC.
Differential methylation was assessed at the CpG level using limma. Next, we compared with human cSCC
Infinium HumanMethylation BeadArray data. Genes were considered to be of major relevance when they
featured at least one significantly differentially methylated CpGs (RRBS) / probes (Infinium) with at least a
30% difference between tumour vs. control in both a murine gene and its human orthologue. The human
EPIC Infinium data were used to distinguish two cSCC subtypes, stem-cell-like and keratinocyte-like tumours.
Findings: We found increased average methylation in mouse cSCC (by 12.8%, p = 0.0011) as well as in stem-
cell like (by 3.1%, p=0.002), but not keratinocyte-like (0.2%, p = 0.98), human cSCC. Comparison of differen-
tially methylated genes revealed striking similarities between human and mouse cSCC. Locus specific meth-
ylation changes in mouse cSCC often occurred in regions of potential regulatory function, including
enhancers and promoters. A key differentially methylated region was located in a potential enhancer of the
tumour suppressor gene Filip1l and its expression was reduced in mouse tumours. Moreover, the FILIP1L
locus showed hypermethylation in human cSCC and lower expression in human cSCC cell lines.
Interpretation: Deregulation of DNA methylation is an important feature of murine and human cSCC that
likely contributes to silencing of tumour suppressor genes, as shown for Filip1l.
Funding: British Skin Foundation, Cancer Research UK
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B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)Introduction
Despite the beneficial effects of ultraviolet radiation (UVR) for e.g.
vitamin D production and skin nitric oxide mediated blood pressurereduction [1,2], solar UVR also poses a major health risk, and is the
main etiological factor for the development of skin cancer. Environ-
mental and lifestyle factors as well as longer life expectancy increase
the cumulative lifetime UV exposure and consequently, skin cancer
rates are increasing [3]. Cancers of the human skin can be classified
within two general types, melanoma and non-melanoma skin cancer
(NMSC). NMSC are largely comprised of keratinocyte cancers, and are
further sub-divided into basal cell carcinoma and squamous cell car-
cinoma (cSCC) [4]. Cutaneous SCC account for at least 20% of all
human skin cancers and their incidence is increasing steeply in age-
ing Caucasian populations [5]. While cure rates for localized cSCC are
as high as 96% when appropriately diagnosed and treated, there are
limited treatment options for advanced and metastatic cSCC [6].
Especially patients from high-risk groups, such as solid organ trans-
plant recipients, face a dismal prognosis as high-risk cSCC often recur,
Research in context
Evidence before this study
Cutaneous squamous cell carcinoma (cSCC) is the most com-
mon human malignancy. While most cSCCs are readily treated
by surgical excision, some cSCC recur and advance to aggressive
stages. Furthermore, high risk groups, such as organ transplant
recipients, have a dramatically increased risk to develop aggres-
sive and metastatic cSCCs. Currently used animal models are
not able to adequately reflect the complex mutational land-
scape of human cSCC. We have previously developed a preclini-
cal mouse model that is histopathologically and genetically
remarkably similar to human cSCC. This model presents a
unique opportunity to study cSCC biology and, more impor-
tantly, test treatment and prevention strategies to improve
cSCC management.
Added value of this study
This study compares DNA methylation in our mouse model to
data from human cSCC. We find that in our model both general
DNAmethylation features and differentially methylated regions
are remarkably similar to human cSCC, further validating it as a
good representation of human cSCC. Additionally, we identify
differentially methylated regions that likely affect target gene
expression and correlate with clinical features in patients.
Implications of all the available evidence
Because slow disease progression in cSCC complicates studies
in humans, good animal models are needed to develop new
prevention and intervention strategies and evaluate their bene-
fits. Currently used models do not reflect the complex genetic
and epigenetic landscape of human cSCC. The histopathological,
genetic and epigenetic similarities between the solar simulated
UV mouse cSCC model and human cSCC make it a valuable tool
to study human cSCC. Furthermore, the differentially methyl-
ated regions identified in our study could serve as biomarkers
to stratify aggressive from non-aggressive cSCC, and indicate
further treatments and improve patient outcomes.
2 K. Roth et al. / EBioMedicine 67 (2021) 103383have high rate of metastasis and treatment options are very limited
[79].
Exposure to UVR causes DNA damage in skin cells such as kerati-
nocytes [10,11] and leads to a very high mutation burden in cSCC
with as much as 1 mutation per 30 kb of coding sequence, making
cSCC the most mutated cancer [12]. The vast majority of these muta-
tions are “UV-signature mutations”, i.e., G to A or C to T transitions,
which makes G- and C-rich genes more likely to become mutated
[13]. Known driver mutations in cSCC are TP53 (early event, <65% of
cSCC), NOTCH (early event, <75% of cSCC), CDKN2A (50% of cSCC, with
additional epigenetic inactivation), and TGFB1 [1416]. Interestingly,
whereas RAS mutations are relatively rare, commonly used animal
models, such as the DMBA/TPA two-stage skin carcinogenesis model
are Ras dependent [17]. To accurately model carcinogenesis and the
complex genetic landscape of cSCC, we subjected SKH-1 hairless
mice to chronic intermittent sub-erythemal doses of solar simulated
UVR (comprised of UVA and UVB wavelengths). This mouse model
produces tumours that are histopathologically and genetically very
similar to human cSCC [1820].
It is becoming increasingly clear that inactivation of tumour sup-
pressor genes plays a major role in cSCC [2123]. In addition to
mutations, tumour suppressor genes are often silenced by DNA
methylation. Furthermore, global DNA hypomethylation in cancercells contributes to genome instability and expression of aberrant
transcripts from repetitive sequences that lead to chromosomal rear-
rangements, mitotic recombination and aneuploidy [2426]. Despite
the global DNA hypomethylation generally found in cancer, pro-
moters of tumour suppressor genes are often hypermethylated and
thereby silenced. Our previous analysis of the mutational landscape
of mouse cSCC tumours from a solar-simulated UV radiation model
(hereafter termed solar-simulated UV mouse cSCC, ssUV mcSCC)
identified members of the Tet gene family among the mutated genes
[20]. Tet genes encode Ten-eleven-translocases that are involved in
DNA demethylation [27], prompting us to investigate potential alter-
ations in DNA methylation in cSCC. In this report, we first present a
genome-scale analysis of the methylome of the ssUV mcSCC tumours,
showing that DNA methylation changes often occur at regions that
have genomic features commonly associated with regulatory func-
tion. We then compare DNA methylation patterns in the mouse
tumours to human primary cSCCs, further validating the clinical rele-
vance of this model.Methods
Ethics
Cutaneous carcinogenesis experiments were performed in accor-
dance with the regulations described in the UK Animals (Scientific
Procedures) Act 1986. Experiments were approved by the Welfare
and Ethical use of Animals Committee of the University of Dundee.
Experimental design was in line with the 3Rs principles of replace-
ment, reduction, and refinement (www.nc3rs.org.uk).Cutaneous carcinogenesis
Tumours and matched control skin samples were obtained from a
previous study [18]. Briefly, SKH-1 hairless mice (Charles River, Ger-
many) were bred in our facility with free access to water and food
(pelleted RM1 diet from SDS Ltd., Witham, Essex, UK), on a 12 h light/
12 h dark cycle, 35% humidity. The experimental animals were age-
matched and female. Starting at 8 weeks of age, the mice were
exposed twice a week for 15 weeks on Tuesdays and Fridays to solar-
simulated UV radiation (comprised of 2 J/cm2 UVA and 90 mJ/cm2
UVB) delivered from UVA340 lamps (Q-Lab, Germany) in clear bed-
ding-free cages. The radiant dose was confirmed with an external
radiometer (X-96 Irradiance Meter; Daavlin, Bryan, OH) before and
after each irradiation session. Excessive heating was prevented by
use of an electrical fan. After the end of the irradiation schedule, the
animals were monitored for a further 20 weeks, and tumours
(defined as lesions >1 mm in diameter) and body weights were
recorded weekly. The mice were then euthanized, individual
tumours, tumour-free dorsal skin, and non-irradiated ventral skin
were harvested, immediately frozen in liquid N2, and stored at 80 °
C. Laser-capture microdissection (on Zeiss Palm Microbeam micro-
scope, Zeiss, UK) was used to enrich for tumour cell populations and
prevent contamination by infiltrating inflammatory cells. Genomic
DNA was extracted from tumour cells and from matched normal skin
samples. The goal of this study was to examine cutaneous squamous
cell carcinomas (cSCC) in mice and the feasibility to use the mouse
model as a model for human cSCCs. Therefore, we studied 7 cSCC
tumour samples in mice. For each tumour sample, a matching control
sample was included from an area of the skin that was not affected
by the tumours. A technical replicate was included for one of the con-
trols as well as one of the tumour samples. Additionally, two inde-
pendent skin control samples were obtained from mice of the same
age as the study group, living under the same conditions, but not
exposed to UV radiation. All samples were subjected to (oxidative)
reduced representation bisulfite sequencing ((ox)RRBS).
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DNA for reduced representation bisulfite sequencing (RRBS) was
obtained using the protocol described in [20]. In brief, mouse skin
tumours were harvested and snap-frozen in liquid N2. Tumour tissue
was enriched using laser capture microdissection and genomic DNA
was isolated using the QIAmp DNA micro kit (Qiagen) according to
the manufacturer‘s protocol. Genomic DNA was then used for oxRRBS
library preparation.
Isolation of RNA and protein for expression and protein quantification
RNA and protein were isolated from fresh frozen tissue using a
combination of TRI reagent (Sigma Aldrich) and the Qiagen AllPrep
DNA/RNA kit. In brief, tissue was pulverized using a mortar. Tissue
powder was lysed with 500 mL RLT Plus buffer, supplemented with
1% v/v b-mercaptoethanol (b-ME). Non-soluble components were
removed by centrifugation and supernatant was mixed with 1 mL of
TRI reagent, incubated for 5 min at room temperature (RT) before
being mixed with 200 mL of chloroform and incubated at RT for
15 min. Phase separation was achieved by centrifugation (15 min,
13000 rpm, 4°C). The colourless, aqueous phase, containing the RNA,
was transferred to a new 2-mL reaction tube and incubated for
15 min at RT after addition of 500 mL 2-propanol. RNA then was
bound to a Qiagen AllPrepDNA/RNA kit RNA column and isolated
according to a modified version of the manufacturer’s protocol. The
organic phase, containing the protein, was mixed with 1 mL 2-propa-
nol to precipitate the protein. Protein was pelleted by centrifugation
(10 min, 13000 rpm, 4 °C). Protein pellets were washed twice using
1 mL wash solution) for 20 min. After the final washing step, protein
pellets were either stored in washing solution at -20 °C or directly
resuspended in 2x SDS buffer.
Library preparation and sequencing
Library preparation and sequencing were performed by NXTGNT
(Ghent, Belgium). Upon arrival, the samples were assessed by Quant-
iTTM PicoGreenTM dsDNA Assay Kit (P7589, ThermoFisher) for quality.
No aberrations were detected, and 1 mg DNA was measured for
MSP1 digestion. Digestion was performed overnight for 16 h at 37 °C
in a volume of 30 ml and stopped with 5 ml of 0.5 M EDTA. Subse-
quently, the digestion product was purified with the GeneJET PCR
Purification Kit (K0701, ThermoFisher), eluted in 50ml elution buffer
and quality was checked again on E-GelTM EX Agarose Gels, 1%
(G401001, ThermoFisher). NEBNext Ultra DNA Library Prep Kit for
Illumina (E7370, New England Biolabs) and TrueMethyl seq kit (Feb
2015, Cambridge Epigenetix) were used for library preparations, both
kits according the manufacturers recommendations. Samples were
splitted into two aliquots (each 275 ng) of which one was oxidated
for oxRRBS. After bisulfite conversion and subsequent clean-up reac-
tion, polymerase chain reaction (PCR) amplification was performed.
Agencourt AMPure XP Bead Clean-up 1:1 (E6260) was performed for
cleanup and DNA fragment length selection. Finally, a DNA high sen-
sitivity chip on the Bioanalyzer (Agilent technologies) and measure-
ments of qPCR quantification according to the Illumina protocol
(“qPCR quantification protocol guide”) concluded the last quality con-
trol steps.
Sequencing was performed on the NextSeq500 using 7 dark cycles
on single read fragments with a length of 76 bp. A concentration of
1.8 pM was loaded with a 15% PhiX spike-in.
Sequence read mapping and summarization
The Mouse reference genome as provided by Ensembl (GRCm38/
mm10) was used for mapping of (ox)RRBS sequencing reads. Quality
control and filtering of low-quality reads was performed using “TrimGalore!” (Babraham Bioinformatics). Quality control indicated no
major problems, so Bismark (v.0.16.3, Babraham Bioinformatics) was
used in Bowtie2-mode [28], for mapping. Seed length, mismatches
and interval during multiseed alignment were set to the default val-
ues.
Differential methylation analysis
The differential methylation analysis was performed in R (v. 3.3.1)
using Bioconductor (v. 2.34.0). After summarization the data were
imported using the BiSeq-package (v. 1.14.0) in R. Comparison
between average methylation percentages of different states (e.g.
cases vs controls) was performed using ANOVA analysis and subse-
quent Tukey post hoc analysis, if more than two groups were com-
pared. Additionally, for correlation calculations, Pearson correlation
was performed.
Raw counts were used to calculate methylation percentages
(b-values, (1)) and subsequently M-values (2), with constant equal to
0.01. M-values were demonstrated to have superior statistical prop-
erties for Infinium HumanMethylation BeadArray data [29], but can
also be applied on methylation sequencing data [30], and yield more
appropriate data to be used with the R Bioconductor limma package
(v. 3.30.13).





1 b þ Cte
 
Cte ¼ 0:01  ð2Þ
The calculation of b- and M-values implies intrinsic normalization
(i.e. biases are largely equal for methylated and unmethylated reads),
therefore no additional normalization between samples was per-
formed. Data were however filtered to improve quality: (i) all loci
that have a minimal coverage lower than 8x were considered insuffi-
ciently informative and were removed from the dataset, (ii) a mini-
mum of 6 methylated reads over all samples was required to be
retained in the dataset for further analysis (i.e. at least some methyla-
tion should be present). Finally, after statistical analysis, the Benja-
mini-Hochberg procedure was used to calculate false discovery rates
(FDR), and set at a threshold of 10% to indicate significance.
Additionally, the clusterSites function from the BiSeq package was
used to search for agglomerations of CpG sites. A minimum of 15
CpGs in maximum 200 bp found in at least 75% of all samples are con-
sidered a potential differentially methylated region (DMR). The BiSeq
package uses beta binomial regression to estimate p-values for each
potential DMR [31].
Comparison with independent data
To evaluate the relevance of the mouse model in a human context,
results were compared with human cSCC Infinium HumanMethyla-
tion BeadArray data created by Rodriguez-Paredes et al. [32]. The
data were downloaded via the ArrayExpress database (accession:
EGAS00001002670) and imported using the wateRmelon package (v.
1.18.0). Probe annotation was obtained using the ChAMPdata pack-
age (v. 2.18.0) which is based on genomic coordinates for the GRCh37
reference genome. Upon importing the data, the filter function was
used to filter out probes with high detection p-values. The same strat-
egy was used for the statistical analysis as for the RRBS data, i.e. linear
models of the M-values by means of limma. Due to the high sample
size (n = 46), and thus more power, compared to the RRBS dataset
(n = 16) a more conservative FDR cut-off (5%) was applied for the
human dataset. Next to assessing differentially methylated loci, we
also evaluated the identification by Rodriguez-Paredes et al. [32] of
stem-cell like and keratinocyte-like tumour samples. The authors
kindly provided tumour group annotation per sample.
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featured at least one significantly differentially methylated CpGs
(RRBS) / probes (Infinium) with at least a 30% difference between
tumour vs. control in both a murine gene and its human orthologue.Clinical impact of methylation changes in human data
To assess the clinical relevance of FILIP1L methylation, human
EPIC Infinium data published by Hervas-Marín et al. were down-
loaded from arrayExpress (https://www.ebi.ac.uk/arrayexpress/
experiments/E-MTAB-8542/files/). Using the original annotation by
the authors, the low-risk group corresponds to samples from initial
invasive carcinoma (n = 10), and the high-risk group to samples from
high-risk non-metastatic carcinoma or metastatic carcinoma (n = 8)
[33]. Differential methylation analysis was performed using limma
on the M-values as described above. Significantly differentially meth-
ylated CpGs within the FILIP1L gene were identified (n = 23) and com-
pared with the clearly differentially methylated CpGs in
keratinocyte-like and stem cell-like tumour samples (i.e. significant
and >30% difference in mean methylation between tumour and con-
trol samples).Human-mouse orthologs
For establishing a human-mouse ortholog gene set, Ensembl was
queried using the biomaRt package (v. 2.24.0) for R. Gene annotation
of the GRCh38 assembly of the human genome contains homology
information and was used in combination with the latest reference
genome for mouse (assembly GRCm38), since this version is the most
complete for gene symbol annotation [34]. BiomaRt gives an indica-
tion whether there is a high likelihood of two genes (one human, one
murine) being orthologous or a low likelihood. In case multiple genes
with a high likelihood were found, the gene with the highest degree
of homology was selected. Also, in case no gene with a high likeli-
hood was found, the gene with the highest percentage of homology
was selected. In both cases, if homology percentages were equal,
genes with an identical gene symbol were preferred over their fellow
candidates. If the latter still resulted in redundant candidates, all
were kept as candidate human-mouse orthologs.Visualization of genomic features in the UCSC genome browser
For visualization and integration of different data sources, results
were presented as genomic tracks for the mouse GRCm38 (mm10)
genome, compatible with usage in the UCSC genome browser. RRBS
results were compiled as BedGraph files (https://genome.ucsc.edu/
goldenpath/help/bedgraph.html). For all significant CpGs, the meth-
ylation percentage is displayed as a positive value (between 0 and 1)
whereas for nonsignificant CpGs, the methylation percentage is dis-
played as a negative value in a different colour. Here and further in
the manuscript statistical significance is defined as mentioned before
(RRBS: FDR<0.10; Infinium: FDR<0.05).
Figures that illustrate genomic features at the DMRs contain the
following UCSC genome browser tracks. Keratinocyte methylation
data were available from He et al. [35] and displayed in the Keratino-
cyte track. Chip-Seq data for CTCF and the H3K27Ac and H3K27me3
histone marks were obtained from the Gene Expression Omnibus
(GEO) using the study of Yu et. al [36]. The deeptools suite [37] was
used to manipulate the obtained files to make them compatible for
UCSC liftover tool, for adaptation of mm9 coordinates to GRCm38
(mm10) coordinates and finally back to the original bigwig format for
usage in the UCSC genome browser. Finally, FANTOM5 TSS activity
data were obtained to investigate whether differential methylation
colocalizes with regulatory domains in the mouse genome [38].Clustering
Clustering was achieved by using the 10,000 most variant loci
over all samples, thereby excluding noise and low informative loci.
As dissimilarity measure, the Euclidian distance based on the covari-
ance of the methylation percentages was used.Cell culture
Human and murine cells, primary cells and cell lines, were cul-
tured under sterile condition in flasks and maintained at 37 °C in a
humidified incubator with 5% CO2 (HERAcellTM incubator). Cells
were ensured to be free of mycoplasma contamination by routine
testing using MycoAlert Mycoplasma Detection Kit (Lonza). Cutane-
ous Squamous Cell Carcinoma cells (cSCC) and normal human kerati-
nocytes (NHK) were isolated from tumour tissue obtained from
patients and from breast or abdominal normal skin of human sub-
jects, respectively, after written and informed consent [22,39]. cSCC
cell lines and NHK cells were maintained in RM+ medium with the
following composition: a mixture of DMEM:Ham's F12 (3:1) (Thermo
Scientific) media supplemented with 10% fetal bovine serum (FBS,
Thermo Scientific), 0.4 mg/mL hydrocortisone (Sigma), 5 mg/mL insu-
lin (Sigma), 10 ng/mL epidermal growth factor (EGF, Serotec), 5 mg/
mL transferrin (Sigma), 8.4 ng/mL cholera toxin (Sigma) and 13 ng/
mL liothyronine (Sigma). The mouse keratinocyte cell line Kera308
(obtained from Cell Lines Service) was maintained in DMEM, supple-
mented with 10% FBS. Filip1l siRNA knockdown in Kera308 cells was
achieved using the reverse transfection protocol of the RNAiMax
reagent kit (Thermo Fischer) according to the manufacturer’s proto-
col. A list of siRNA assays can be found as supplementary informa-
tion.Isoform specific qPCR
RNA was extracted and converted to cDNA using the Qiagen
Omniscipt RT kit with a modified (50% reduced RT enzyme concen-
tration) version of the manufacturer’s protocol and random hexamers
(Invitrogen). qPCRs were performed using a standard Taqman proto-
col on the QuantStudio 5 RT-PCR system (Thermo Fischer). Isoform
specific Taqman probes were designed using Primer Quest online
tool from Integrated DNA technologies (see https://www.idtdna.
com/PrimerQuest) and sequence specificity was ensured by BLAST
against the host genome and transcripts. A list of Taqman assays can
be found as supplementary information.Immunoblotting
Proteins were separated using precast polyacrylamide (10% or
412%) Bis-Tris gels (Invitrogen), and MOPS (Invitrogen) as running
buffer. Proteins were transferred to a 0.45 mm supported nitrocellu-
lose membrane (Amersham  GE Healthcare Life Sciences). Transfer
was completed in 1x Transfer buffer, supplied with 0.1% SDS at 100 V
for 90 min using a wet transfer system. Membranes were blocked
using 5% non-fat milk in 1x TBS for 1 h at room temperature. Primary
antibodies were prepared in 0.1% non-fat milk in 1x TBS-T in appro-
priate dilutions and incubated with the membrane on a roller at 4 °C
overnight. Membranes were washed 3 times for 15 min using 1x
TBS-T. Secondary antibodies were diluted 1:15,000 in 0.1% non-fat
milk in 1x TBS-T and incubated for 1 to 2 h at room temperature.
Excess secondary antibody was washed off as described for primary
antibodies. Image capture and analysis were done using the
Odyssey CLx image system and Image Studio software (LI-COR). A
list of used antibodies can be found as supplementary information.
Fig. 1. Cluster analysis indicates larger difference between tumours and controls than
between individuals. T and C indicate tumour and control samples respectively, the
number indicates the animal of origin and finally, technical replicates are indicated by
an “*”. C,8 and C,9 represent the two independent healthy skin samples which cluster
with the other control samples, indicating that methylation does not discriminate nor-
mal ventral from dorsal skin. Tumour and control samples cluster separately, indicat-
ing profound methylation changes between the two groups. Cluster analysis was
performed using the 10,000 most variant loci.
Fig. 2. Average methylation is significantly higher in mouse ssUV cSCC compared to
matched controls. Note that average methylation levels are based on the results from
86,508 sufficiently covered CpGs in the RRBS data (< 0.4% of all mouse CpGs), which
are not necessarily representative for the full genome.
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The funding bodies had no influence on study design, data collec-
tion, data analyses, interpretation, or writing of report.
Results
DNA methylation discriminates between murine tumours and normal
skin
We analysed DNA methylation and hydroxymethylation changes
in cSCC tumours obtained from our previously developed ssUV
mcSCC model [18,20]. Six laser-capture micro-dissected tumour sam-
ples, six matched controls (non-irradiated ventral skin from the same
animal), and two independent healthy skin samples (dorsal skin from
age-matched animals) were subjected to oxidative reduced represen-
tation bisulfite sequencing (oxRRBS). Two technical replicates (one
tumour, one matched control) were included to control for data qual-
ity. The analysis of the levels of 5hmC showed that hydroxymethyla-
tion was extremely low and therefore not distinguishable from noise
(see Supplementary Figure 1). We therefore used the conventional
RRBS data throughout the remainder of this study.
Based on clustering of the samples (Fig. 1), changes due to tumour
proliferation are more evident than differences between individuals,
i.e. the highly disruptive character of skin cancer is also observable atthe DNA methylation level. Furthermore, the cluster analysis shows
that technical replicates cluster together, indicating good quality of
the data. Technical replicates were therefore merged and treated as a
single sample in further analyses.Average DNA methylation is higher in tumours compared to controls
In most cancers, large stretches of intergenic DNA become hypo-
methylated, while DNA methylation at CpG islands become either
hypo- or hypermethylated leading to a global decrease in DNA meth-
ylation levels [40,41].
We detected a 12.8% (p = 0.0011; ANOVA with Tukey post hoc)
increase in average DNA methylation in murine tumour samples
(Fig. 2). However, note that our RRBS strategy only analysed a sub-
fraction (86,508 CpGs) of the approximately 22 million CpGs present
in the murine genome (GRCm38/mm10 assembly), typically in CpG
dense regions, which may confound the extrapolation of this conclu-
sion to the full genome.Differentially methylated regions co-localize with regulatory elements
Differential methylation was assessed at the CpG level using
limma, resulting in 640 differentially methylated CpGs in 318 unique
genes (see Supplementary Table 1). However, here we particularly
focus on differentially methylated regions (DMR), as these are
deemed to have more impact than individual CpGs. Using the BiSeq
package, 78 significantly differentially methylated regions (DMRs)
were found in tumours versus controls (76 hypermethylated, 2 hypo-
methylated). The top 20 DMRs are depicted in Table 1 (for full DMR
list see Supplementary Table 2). Median differences in methylation
ranged from -13% to 40% (positive values indicate increased methyla-
tion in tumours). The most striking result was a DMR on chromosome
16 (position 57,391,482-57,391,657) that featured the largest differ-
ence in methylation (40% increased median methylation in tumours).
The region overlaps with two genes on opposite strands, Filip1l and
Cmss1.
Table 1
Top 20 DMRs with the highest difference in methylation between controls and tumours. Of the top 20 DMRs, 19 are hypermethylated and only 1 is hypomethylated in tumours
compared to controls. The most differentially methylated DMR is located on chromosome 16 and overlaps with two genes encoded on opposite strands: Filip1l and Cmss1.
Median methylation
Gene Type Chromosome Start End Width # CpGs Median p FDR Control Tumours difference
Filip1l genic 16 57391482 57391657 176 38 0,0001421 0,0090997 34,23% 76,02% 39,87%
intergenic 3 5860619 5860741 123 30 0,0013334 0,0613401 24,67% 57,86% 33,16%
intergenic 12 112802696 112802752 57 9 0,0018667 0,0709347 13,80% 38,92% 25,12%
intergenic GL456378.1 27849 27988 140 18 0,0002308 0,0140796 12,44% 38,05% 24,52%
Rbmxl2 genic 7 107210000 107210046 47 24 0,0033155 0,0943661 38,22% 59,05% 20,82%
Sp8 genic 12 118849494 118849660 167 23 0,0010454 0,0491377 7,77% 25,01% 17,23%
Adra2c genic 5 35280820 35280957 138 21 0,0032540 0,0943661 13,46% 29,93% 16,01%
Hapln4 genic 8 70088183 70088238 56 9 0,0000565 0,0039047 4,14% 19,43% 15,29%
Foxd3, Gm23366,
Gm12688
promoter 4 99656874 99656946 73 13 0,0014836 0,0667642 6,11% 20,53% 14,41%
Gm42418 promoter 17 39845285 39846122 838 123 0,0004844 0,0256759 14,54% 31,16% 13,47%
Cdk8 genic 5 146261012 146261147 136 24 0,0000006 0,0000511 8,42% 21,89% 13,47%
intergenic 11 109011699 109011975 277 37 0,0000031 0,0002340 17,71% 31,59% 13,44%
C1ql2 promoter 1 120341073 120341333 261 15 0,0082421 0,1127978 8,89% 22,08% 13,19%
Gm42418,
AY036118
promoter 17 39847522 39847638 117 2 0,0245761 0,1127978 18,49% 31,49% 13,00%
Rims1 genic 1 22533835 22533906 72 10 0,0016663 0,0678245 5,20% 18,05% 12,86%
intergenic 12 57538740 57538787 48 8 0,0070264 0,1127978 6,54% 18,45% 11,87%
promoter 17 39846535 39846769 235 14 0,0052170 0,1103093 14,54% 34,12% 11,68%
Gabra5 promoter 7 57509682 57509946 265 17 0,0027055 0,0865786 4,65% 14,80% 10,86%
Gm26917 genic 17 39844548 39844900 353 68 0,0055337 0,1103093 10,53% 20,33% 9,73%
intergenic 2 98666262 98666273 12 4 0,0093025 0,1127978 81,05% 67,73% -13,34%
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ing DMRs. As shown in Fig. 3, the DMR covering intronic regions of
Cmss1 and Filip1l is hypermethylated in tumours. ChIP-Seq data from
mouse skin [36] show occupancy of the region by CTCF as well as the
H3K27me3 and H3K27Ac histone marks. While CTCF can block com-
munication between enhancers and promoters [42], H3K27me3 is a
mark found at repressed enhancers and has a mutually exclusive
relationship with H3K27Ac, a mark of active enhancers [43,44]. We
therefore hypothesize that differential methylation at the region
affects enhancer activity [45]. The region in which the DMR resides is
an intron for which transcriptional activity is observed (see FAN-
TOM5 TSS activity tracks SkinAdult - and +), in line with enhancer
RNA expression, a common occurrence at enhancers [46]. In sum-
mary, the genomic features of the region suggest that it is likely an
enhancer, potentially controlling expression of the nearby gene Fil-
ip1l. As Filip1l encodes a tumour suppressor [4749], we further
focus on this locus for subsequent analyses.
We found genomic features similar to those found at the Filip1l
locus at multiple other DMRs (see supplementary information). As
tumour suppressor gene inactivation is an important feature of cSCC
[2123], differential methylation at regions of potential regulatory
relevance is likely an important process of tumour suppressor silenc-
ing in cSCC as indicated by the Filip1l locus.
DNA methylation is similar in ssUV mcSCC and human cSCC
Data from previous studies suggest that the ssUV mcSCC model is
a good representation of human cSCC in terms of genetics and histo-
pathology [19,20]. To elucidate if DNA methylation in the ssUV
mcSCC model represents human cSCC, we used data from Rodriguez-
Paredes et al. [32], who analysed DNA methylation patterns of 34
human skin samples (including 18 cSCC and 16 human actinic kerato-
sis (AK), the precursor lesion of cSCC) using Illumina’s Infinium EPIC
850k arrays. Independent of the precursor status, they found two
subclasses of AK and cSCC, termed keratinocyte- and stem cell-like,
featuring major DNA methylation differences at keratin gene clus-
ters.
Since average methylation was significantly higher in ssUV mcSCC
tumours compared to controls in our dataset, we evaluated whetherthis was also the case in human cSCC. Using the data from Rodriguez-
Paredes et al. [32], there were no overall differences between con-
trols, AK and cSCC (Fig. 4a). However, average DNA methylation was
significantly higher in the stem cell-like class compared to controls
(by 3%, p = 0.01; ANOVA with Tukey post hoc; Fig. 4b), but was not
increased in the keratinocyte class (0.2%, p = 0.98; ANOVA with Tukey
post hoc). Moreover, cluster analysis of the human methylation data
indicated that the large majority of stem cell-like samples clusters
separately from controls and keratinocyte-like samples (Fig. 4c), sup-
porting major general methylation differences between both AK and
cSCC subclasses. Together, these findings suggest that an increase in
DNA methylation levels correlates with a cSCC stem cell-type and
aggressiveness and that the ssUV mcSCC model may represent a
more aggressive cSCC type.
As DMRs cannot be readily compared between mouse and
human, as well as between different platforms (RRBS versus Infin-
ium array), we focused on genes containing differentially methyl-
ated CpGs in both species. Since our results support the presence
of two distinct subtypes, i.e. keratinocyte and stem-cell like, analy-
ses are performed for both subtypes separately. We found 376,297
(= 43.8%) and 362,447 (= 42.2%) significantly differentially methyl-
ated CpG dinucleotides in 27,187 (= 87.6%) and 25,877 (= 83.3%)
unique genes respectively for keratinocyte and stem-cell like
tumour samples in the human Infinium data (Supplementary
Tables 3 and 4). We then selected genes that had at least one differ-
entially methylated CpG in the murine data, resulting in a set of
265 genes with their human ortholog. Remarkably, these genes
were more likely to be significantly differentially methylated in
human tumours: 93.5% and 90.6% genes contained at least one dif-
ferentially methylated CpG, compared to the respective baselines
of 87.6% and 83.3% for keratinocyte and stem-cell like tumour sam-
ples respectively (chi-squared test, Bonferroni adjusted P-val-
ues = 0.0083 and 0.0044). In line with the hypermethylation
observed in stem-cell like and murine cases, the direction of the
methylation difference was significantly more concordant with
stem-cell than with keratinocyte like samples (82.5% and 65.7%;
chi-squared test, P-value = 3.8E-5).
Subsequently, we focussed on genes most likely playing a major
role in cSCC, i.e. showing at least one clearly differentially methylated
Fig. 3. Methylation and genomic features of the DMR at the Filip1l locus. The Filip1l DMR is the most differentially methylated region we detected. The Keratinocyte track shows all
CpG positions in the mouse genome. Note that RRBS does not cover all CpGs and therefore, only data for covered CpGs is displayed in the following tracks. Methylation levels in ven-
tral skin controls and tumours are visualized in Control and Tumour tracks. Genomic features of at the Filip1l locus suggest that the region is likely an enhancer. The region is occu-
pied by CTCF, as well as the mutually exclusive histone marks H3K27me3 (repressive) and H3K27Ac (activating). Furthermore, transcriptional activity at the DMR, highlighted in
the FANTOM5 TSS activity track (“SkinAdult”) may resemble enhancer RNAs. We hypothesise that DNA methylation status of the region influences the enhancers activity.
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and murine data. For both keratinocyte and stem-cell like tumour
samples, we found the Filip1l and Cmss1 genes to be differentially
methylated in both, human and mouse cSCC. Filip1l/Cmss1 are located
at the most differentially methylated region and their hypermethyla-
tion in human cSCC highlights the importance of the genes. Addi-
tional genes identified include Tspan9, Hoxd3/Hoxd4, Abr, Gpc6,
Gal3st3, Sept9 and Lbra/Mab21l1. This analysis also yielded some sub-
type specific results: Tcfl5, Rgma, Galnt13, Slc2a10 and R3hdm4 for
stem-cell like cSCCs, but no additional genes for keratinocyte-like.
When focusing solely on promoter regions, similar trends were
observed, yet typically less outspoken and with fewer overlap
between genes, largely due to the fact that many relevant promoters
were not covered by RRBS. Overall, the remarkable similarities in the
methylomes of human and mouse ssUV cSCC show that the tumours
that form in the ssUV mcSCC model, in addition to theirhistopathology and genetics, are also similar to human cSCC on the
DNA methylation level, thus highlighting the clinical relevance of this
model.
Differential methylation at the Filip1l locus affects Filip1l expression
As described earlier, we detected a DMR in an intronic region of
the Filip1l gene that shows genomic features commonly associated
with enhancers. Since there is no published information about the
role of Filip1l in the skin, we subsequently characterized the isoform
composition and expression of Filip1l in the mouse skin. By utilizing
a combination of isoform specific qPCR probes and isoform specific
siRNAs, we determined that Filip1l isoform 202 (Ensemble annota-
tion) is the only expressed isoform in mouse skin and the mouse ker-
atinocyte cell line Kera308 (Fig. 5). Interestingly, this isoform shows
high similarities to the human FILIP1L isoform 203 (91% identity as
determined by protein blast, Ensemble annotation), which has been
Fig. 4. a: Average methylation of human skin samples (control), AK and cSCC. No difference in average methylation between the groups was detected. b: Average methylation of
control samples and AK and cSCC samples, identified as keratinocyte like of stem cell like. Average methylation is significantly higher in stem cell like samples compared to both
control and keratinocyte like samples. Significance is indicated by asterisks (ANOVA with Tukey post-hoc correction, * p < 0.05, ** p < 0.01, *** p < 0.001). c: Cluster plot: HSo and
HSy are control samples, cSCC and AK are tumour samples; for the latter K and S indicate whether the sample is respectively a keratinocyte like or stem cell like cancer sample.
With the exception of three keratinocyte-like samples, average methylation separates controls as well as keratinocyte-like and stem cell-like AK and cSCC samples.
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atic and prostate cancer, and is an independent prognostic marker in
ovarian cancer [47,5053].
In order to determine expression of the Filip1l protein in mouse
cSCC tumours and control skin, immunoblotting was used. A total of
54 samples from 18 animals (three samples per animal: ventral skin
(VS, matched control, non-irradiated), dorsal skin (DS, chronically
irradiated but not tumourous) and tumour (numbers indicate animal
designations) were analysed as shown in Fig. 6a,b. Using fluorescence
detection immunoblotting (LI-COR), we quantified the Filip1l protein
levels in all samples using a-tubulin as loading control. The Filip1l
protein levels were significantly reduced in chronically-irradiated DS
compared to non-irradiated VS (paired t-test, p = 0.03). Furthermore,
in murine cSCC tumours, the Filip1l protein levels were further
reduced compared to VS (paired t-test, p = 0.0026). Additionally,
Fig. 6c shows the quantification of FILIP1L protein levels in a panel of
12 human cSCC cell lines [39]. Compared to the mean of three cul-
tures of primary human keratinocytes (NHK), FILIP1L protein levels
were increased in one cSCC cell line (T2), similar to NHK in 4/12 cSCC
cell lines (IC1 met, Met1, Met4 and T9) and lower (i.e. below 2/3 of
NHK means) than NHKs in 7/12 cSCC cell lines (IC1, IC8, IC18, IC19,
Met2, T8 and T10).
Having confirmed that differential FILIP1L methylation and
expression is also present in human cSCC, we evaluated its clinical
relevance in humans using Infininium MethylationEPIC data pro-
vided by Hervas-Marín et al. for 10 low (initial invasive carcinoma)
and 8 high-risk (high-risk non-metastatic carcinoma and metastatic
carcinoma) samples [33]. Note that a high-risk assessment is associ-
ated with a higher frequency of local recurrence, lymph node metas-
tasis and significant morbidity and mortality and thus helps
identifying patients with poor outcomes. For the FiILIP1L gene, 23
CpG were differentially methylated (FDR < 0.05) between high- and
low-risk samples. Of these, 9 had also been found to be clearly
(>30%) and significantly differentially methylated in human stemcell-like samples (and less clearly, but for the majority still signifi-
cantly, in keratinocyte samples) vs. controls. The direction of differen-
tial methylation for high-risk vs. low-risk was the same as for tumour
vs. controls for 8 out of 9 probes (P < 0.05, binomial test), the non-
consistent CpG being situated in the 3’ UTR; see Fig. 6d). This finding
demonstrates that Filip1l methylation differences in the murine
model are not only also present in human cases vs. controls, but are
also clinically relevant.
Discussion
The biology of cSCC, a type of tumour with an enormous muta-
tional burden and no clear drivers of disease progression, is incom-
pletely understood. In this study, we show that in contrast to most
cancers which are characterized by global DNA hypomethylation,
hypermethylation defines the methylome of cSCC. Our findings are
supported by independent reports showing a pattern of DNA hyper-
methylation in high-risk non-metastatic and metastatic human cSCC
[33]. Using the Infinium MethylationEPIC BeadChips 850K array (Illu-
mina Inc. USA), these researchers found that, in addition to CpG
islands, the increase in DNA methylation also occurs at CpG shelves,
shores and open sea, next to CpG islands, suggesting that the
observed hypermethylation is genome-wide. Moreover, considering
that in cSCC most mutations do not occur within oncogenes, but
within tumour suppressor genes [8,54,55], our findings indicate that
in addition to loss-of-function mutations, changes in DNA methyla-
tion have a role in silencing tumour suppressor genes in cSCC.
Together, these findings suggest that DNA methylation changes
are significant contributors to tumour progression in cSCC and offer
potential therapeutic approaches with small molecules that have the
ability to alter the DNA methylome. One example is the isothiocya-
nate sulforaphane, a compound that has shown protection against
UV radiation-induced skin damage in both mice and humans [56],
and currently is in clinical trials for several disease indications [57].
Fig. 5. a: Isoform-specific qPCR for Filip1l in mouse ventral skin (VS, n = 8) and the mouse keratinocyte cell line Kera308. Results for Kera308 cells represent the mean of three tech-
nical replicates, error bars represent standard deviation. VS: Ventral skin, numbers indicate animal designation. The expression of isoforms 201 and 203 is minimal compared to the
expression of isoform 202. We therefore conclude that isoform 202 is the main expressed isoform in mouse ventral skin. b: Protein levels of Filip1l after siRNA treatment at 24- and
48-hours post-transfection. The used siRNAs target two isoforms, either 201 and 203, or 202 and 203. si 201/203 and si 202/203 experiments use two siRNAs each, si 201/202/203
use the combination of 4 siRNAs. The combination of siRNAs targeting all Filip1l isoforms completely abolishes Filip1l protein expression, while siRNAs targeting isoforms 201 and
203 do not have an effect on Filip1l protein levels. Treatment with siRNAs targeting isoforms 202 and 203 also suppress Filip1l expression. This confirms the finding from the mRNA
analysis, that Filip1l isoform 202 is the main expressed isoform in Kera308 cells.
K. Roth et al. / EBioMedicine 67 (2021) 103383 9Importantly, sulforaphane has been shown to attenuate a number of
UVR-induced DMRs, e.g. within Notch1 and Smad6, in the mouse skin
and reduce the incidence and multiplicity of skin cancer [58], in
agreement with our early observations using broccoli extracts as
delivery vehicles for sulforaphane [59,60].
One limitation of our study is the lack of available data for clinical
outcomes in patients with cSCC. These tumours are visible and surgi-
cally excised shortly after diagnosis in order to prevent the possibility
for metastatic spread, which has precluded us from correlating our
findings with clinical outcomes. Another limitation of our study is
that the precise function of FILIP1L in skin and cSCC remains
unknown. Further investigations are needed to determine the impor-
tance of the observed downregulation of FILIP1L for the development
of cSCC, and the underlying molecular mechanism(s). The majority of
the available functional studies on FILIP1L have focussed on its role in
modulating the WNT/b-catenin signalling pathway. FILIP1L has been
shown to facilitate the destruction of b-catenin and therefore supress
canonical WNT/b-catenin signalling [53,61,62], but the exact mecha-
nism remains unknown. In this context, it is noteworthy that the
study by Hervas-Marín et al. [33] identified the WNT/b-cateninsignalling pathway as one of the potential pathways that are dysregu-
lated in the transition of human cSCC to a high-risk stage. Though
alternative RRBS data analysis methods such as the differential meth-
ylation analysis package (DMAP) [63] could have further improved
the robustness of our results, it should be noted that we used two dif-
ferent methods, i.e. BiSeq (at DMR level) and limma (at CpG level),
leading in both cases to the same conclusion for FILIP1L, which we
further validated by evaluating its methylation in human cSCC
tumours and assessing its protein levels in mouse skin and skin
tumours, and in human keratinocytes and cSCC cell lines.
Interestingly, a recent RNA-seq analysis in BT20 breast cancer
cells (which carry an activating PIK3CA mutation) identified FILIP1L
as the most upregulated gene following treatment with vitamin C,
and further implicated KDM5-mediated H3K4 demethylation in the
mechanism of FILIP1L upregulation [64] suggesting that in addition to
DNA methylation, histone H3K4 methylation has a role in the regula-
tion of FILIP1L expression. It is also noteworthy that in ovarian, pros-
tate and pancreatic cancer, FILIP1L expression is silenced by DNA
hypermethylation; this has been linked to aggressiveness and meta-
static potential, and is even considered an independent prognostic
Fig. 6. a,b: Filip1l protein levels in VS, DS and tumours of SKH-1 hairless mice that had been chronically exposed to UV radiation. a: Representative immunoblot for 4 out of 18 ani-
mals. The numbers on the top indicate individual animals. Filip1l is detected as a band at 110 kDa, consistent with its molecular weight of 98 kDa. Filip1l appears as a double band
in murine skin. b: Quantification of Filip1l protein levels in all 18 animals. Filip1l protein levels are significantly reduced in DS compared to VS and further reduced in tumours com-
pared to VS. Significance is indicated by asterisks (one-tailed paired t-test; * p < 0.005, **p < 0.01, ***p < 0.001). c: FILIP1L protein levels in 3 primary cultures of normal human ker-
atinocytes (NHK, green) and 12 human cSCC cell lines (red). The red line indicates the mean FILIP1L protein levels in NHKs. FILIP1L protein levels are reduced in 7/12 cSCC cell lines.
d: Methylation difference between high- and low-risk cSCC. Most CpGs at the FILIP1L locus are hypermethylated in human high-risk cSCC compared to low-risk cSCC (Hervas-Marín
data [33]). Furthermore, 7/23 of these CpGs were also hypermethylated (>30%, indicated in blue) in stem-cell like compared to keratinocyte like human cSCC Rodriguez-Paredes
data [32]) and 2 CpGs were hypomethylated (<30%, indicated in green).
10 K. Roth et al. / EBioMedicine 67 (2021) 103383marker in ovarian cancer [47,5053]. It is therefore tempting to spec-
ulate that the hypermethylation and lower expression of FILIP1L in
cSCC has a similar role. Further research is needed to test this possi-
bility. Nonetheless, our study clearly shows that DNA methylation at
the FILIP1L promoter is increased in high-risk human cSCC as com-
pared to low-risk cSCC. Methylation biomarkers discriminating low-
from high-risk cSCC, such as the FILIP1L locus, may identify patients
benefitting from a more aggressive treatment regime and could
therefore be a valuable tool to lower the number of recurring cSCC.
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